LLY Maintained by Morgan Stanley -- Price Target Raised to $1430
Morgan Stanley maintained an 'Overweight' rating on Eli Lilly (LLY) and raised its price target to $1430. The company's GF Value™ suggests it is 24.4% undervalued, with a GF Score™ of 96/100. Insider selling activity has been significant, totaling $15.96 million over the past three months.
How this was made
The 30-second read
Why it matters
The upgrade may prompt short‑term buying, but the modest target lift suggests limited upside.
Market read
A fresh analyst rating change for a mega‑cap pharma stock, offering a modest bullish catalyst.
What to watch
The price target increase is modest (0.78%) and may already be priced in; valuation still appears high relative to peers.
Background
Morgan Stanley's analyst team reaffirmed an Overweight stance on Eli Lilly, citing its cardiometabolic pipeline.
Ticker impact
Morgan Stanley maintained an Overweight rating on Eli Lilly and raised its price target to $1,430.
likely upward pressure as investors price in the higher target
The rating change is a fresh, primary disclosure and the target increase is modest but signals confidence in growth prospects.
Market effects
Positive outlook for the broader pharma sector as Lilly's cardiometabolic franchise is highlighted.
U.S. large‑cap healthcare stocks may see modest gains.
Limited to investors tracking major U.S. drug makers.
Counterpoint
Insider selling of $15.9 M in the past three months could signal concerns despite the rating upgrade.
Key entities
- companyEli Lilly and Co.
US‑listed pharmaceutical company (ticker LLY).
- analyst_firmMorgan Stanley
Equity research firm providing the rating update.
